The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness

Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.

By Michael McCaughan

When Pharmaceutical Research & Manufacturers of America CEO Billy Tauzin talks about the dangers of government-run cost effectiveness systems, he...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet